If you have ever visited VCU Massey Cancer Center’s Thomas Palliative Care Unit, you have likely seen the effort nurses and staff make to provide a unique, home-like atmosphere for patients and their loved ones. With that effort in mind, palliative care nurse manager Clareen Wiencek, Ph.D., adopted the idea of Palliative Care on Wheels. With funds provided by the Medical College of Virginia Hospitals (MCVH) Auxiliary, the palliative care unit developed a cart full of materials for activities that would offer comfort to patients and their families, as well as tools for the nurses to enhance care.
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal Blood, are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.
The “Life and Love After Cancer” campaign is intended to lift the spirits of the cancer community by sharing inspirational stories submitted by real people who are embracing their second chance at life. Through a mix of digital, social and traditional media, including billboards and print, TV, radio and online banner ads, the campaign encourages survivors to share how they’re loving life after cancer by submitting their stories and photos here.
Clinical trial studies effectiveness of diet and exercise in preventing gynecologic cancer recurrence
The Gynecologic Oncology Group is leading a nationwide phase III clinical trial called the “Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIvES)” study. Led locally by Weldon Chafe, M.D., Dianne Harris Wright Professor of Gynecology Oncology at VCU Massey Cancer Center, this trial is the first to study if diet and exercise can affect cancer recurrence in women treated for ovarian, fallopian tube or primary peritoneal cancer. Ovarian cancer begins in the female reproductive glands called ovaries. Ovarian cancer accounts for about 3 percent of all cancers in women.
Andrew Poklepovic, M.D., is leading two clinical trials for melanoma at Massey. One trial studies the effects of investigational drug ipilimumab, a biological agent that has been shown to have anti-tumor activity in advanced (stage 4) melanoma, versus FDA-approved drug interferon alpha-2b, which has been shown to reduce the risk of melanoma returning in a portion of patients. The other clinical trial is a phase 2 study that tests a combination therapy of experimental drugs on patients who have a genetic mutation called B-Raf gene (BRAF V600E).